Mesa Laboratories, Inc. (MLAB)
NASDAQ: MLAB · Real-Time Price · USD
139.10
+2.19 (1.60%)
Nov 11, 2026, 3:55 PM EST - Market open
Mesa Laboratories Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 251.32 | 249.13 | 240.98 | 216.19 | 219.08 | 184.34 | |
Revenue Growth | 2.48% | 3.38% | 11.47% | -1.32% | 18.85% | 37.63% |
Cost of Revenue | 88.43 | 90.86 | 88.88 | 81.71 | 85.39 | 75.25 |
Gross Profit | 162.89 | 158.27 | 152.1 | 134.48 | 133.69 | 109.09 |
Selling, General & Admin | 116.7 | 119.45 | 115.02 | 111.49 | 109.88 | 88.62 |
Research & Development | 20.05 | 20.31 | 19.52 | 19.3 | 20.49 | 15.77 |
Operating Expenses | 136.75 | 139.76 | 134.53 | 130.79 | 130.37 | 104.39 |
Operating Income | 26.14 | 18.51 | 17.57 | 3.69 | 3.32 | 4.7 |
Interest Expense | -10.13 | -10.69 | -11.86 | -5.7 | -4.77 | -3.89 |
Currency Exchange Gain (Loss) | -6.63 | - | - | - | - | - |
Other Non Operating Income (Expenses) | 4.01 | 4.2 | -1.4 | 2.12 | 1.06 | 2.76 |
EBT Excluding Unusual Items | 13.39 | 12.01 | 4.31 | 0.11 | -0.39 | 3.57 |
Merger & Restructuring Charges | - | - | -1.23 | -1.23 | - | - |
Impairment of Goodwill | - | - | - | -156.89 | - | - |
Asset Writedown | - | - | - | -117.64 | - | - |
Other Unusual Items | - | - | 2.89 | - | - | - |
Pretax Income | 13.39 | 12.01 | 5.96 | -275.65 | -0.39 | 3.57 |
Income Tax Expense | 6.73 | 5.3 | 7.94 | -21.4 | -1.32 | 1.7 |
Net Income | 6.67 | 6.71 | -1.97 | -254.25 | 0.93 | 1.87 |
Net Income to Common | 6.67 | 6.71 | -1.97 | -254.25 | 0.93 | 1.87 |
Net Income Growth | - | - | - | - | -50.29% | -42.85% |
Shares Outstanding (Basic) | 6 | 6 | 5 | 5 | 5 | 5 |
Shares Outstanding (Diluted) | 6 | 6 | 5 | 5 | 5 | 5 |
Shares Change | 3.52% | 2.66% | 0.65% | 0.47% | 0.49% | 4.12% |
EPS (Basic) | 1.19 | 1.22 | -0.36 | -47.20 | 0.17 | 0.36 |
EPS (Diluted) | 1.18 | 1.21 | -0.36 | -47.20 | 0.17 | 0.35 |
EPS Growth | - | - | - | - | -51.43% | -45.31% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 49.45 | 39.58 | 42.56 | 41.57 | 23.44 | 34.79 |
Free Cash Flow Per Share | 8.75 | 7.11 | 7.85 | 7.72 | 4.37 | 6.52 |
Dividend Per Share | 0.640 | 0.640 | 0.640 | 0.640 | 0.640 | 0.640 |
Dividend Growth | 0% | 0% | 0% | 0% | 0% | 0% |
Gross Margin | 64.81% | 63.53% | 63.12% | 62.20% | 61.02% | 59.18% |
Operating Margin | 10.40% | 7.43% | 7.29% | 1.70% | 1.52% | 2.55% |
Profit Margin | 2.65% | 2.69% | -0.82% | -117.61% | 0.43% | 1.01% |
Free Cash Flow Margin | 19.68% | 15.89% | 17.66% | 19.23% | 10.70% | 18.87% |
EBITDA | 48.81 | 41.78 | 42.1 | 35.26 | 36.45 | 29.77 |
EBITDA Margin | 19.42% | 16.77% | 17.47% | 16.31% | 16.64% | 16.15% |
D&A For EBITDA | 22.67 | 23.27 | 24.53 | 31.57 | 33.13 | 25.07 |
EBIT | 26.14 | 18.51 | 17.57 | 3.69 | 3.32 | 4.7 |
EBIT Margin | 10.40% | 7.43% | 7.29% | 1.70% | 1.52% | 2.55% |
Effective Tax Rate | 50.22% | 44.13% | 133.12% | - | - | 47.65% |
Revenue as Reported | 249.13 | 249.13 | 240.98 | 216.19 | 219.08 | 184.34 |